Leukemia & Lymphoma最新文献

Arsenic trioxide neurotoxicity in acute promyelocytic leukemia patients: a single center experience.

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2024-11-08 DOI: 10.1080/10428194.2024.2427266

G Arrigo, M Scaldaferri, E Audisio, E Boscaro, F Catania, F Cattel, L Celona, M Cerrano, R Freilone, V Giai, I Urbino, S D'Ardia, C Frairia

引用次数: 0

Drug exposure and measurable residual disease in chronic lymphocytic leukemia: a systematic review.

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2024-11-07 DOI: 10.1080/10428194.2024.2412289

Cathrine Korsholm, Cille Bülow, Mikkel Christensen, Kim Dalhoff, Joshua Buron Feinberg, Trine Meldgaard Lund, Carsten Utoft Niemann, Tonny Studsgaard Petersen, Michael Asger Andersen

{"title":"Drug exposure and measurable residual disease in chronic lymphocytic leukemia: a systematic review.","authors":"Cathrine Korsholm, Cille Bülow, Mikkel Christensen, Kim Dalhoff, Joshua Buron Feinberg, Trine Meldgaard Lund, Carsten Utoft Niemann, Tonny Studsgaard Petersen, Michael Asger Andersen","doi":"10.1080/10428194.2024.2412289","DOIUrl":"https://doi.org/10.1080/10428194.2024.2412289","url":null,"abstract":"For fixed-duration therapies against chronic lymphocytic leukemia (CLL), undetectable measurable residual disease (MRD) predicts overall and progression-free survival more accurately than complete remission. For indefinite therapies, MRD status can direct discontinuation of treatment. We systematically reviewed the relationship between antineoplastic drug exposures and undetectable MRD in CLL. Seventeen trials from MEDLINE and EMBASE met the inclusion criteria; four of which evaluated drug exposures in relation to MRD status. Undetectable MRD was associated with higher trough concentrations of ofatumumab and alemtuzumab, as well as increased maximum concentration and area under the plasma concentration curve (AUC) of ibrutinib. One study found an association between high rituximab AUC and undetectable MRD until adjusting for tumor burden. The limited studies, lack of exposure measurements of concomitant drugs, and high heterogeneity in designs limit the results' generalizability. Further research is needed to explore the exposure-MRD relationship and the possibility for therapeutic drug monitoring in CLL.","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":null,"pages":null},"PeriodicalIF":2.2,"publicationDate":"2024-11-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142604917","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Clinical outcomes of patients diagnosed with SETBP1 mutated myeloid neoplasms. 确诊为 SETBP1 基因突变骨髓性肿瘤患者的临床疗效。

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2024-11-06 DOI: 10.1080/10428194.2024.2425048

Yazan Jabban, Mahmoud Yacout, Anmol Baranwal, Rong He, David Viswanatha, Patricia Greipp, Dragan Jevremovic, Kurt Bessonen, James Foran, Jeanne Palmer, Antoine N Saliba, Mehrdad Hefazi-Torghabeh, Kebede Begna, William J Hogan, Abhishek Mangaonkar, Mrinal Patnaik, Mithun Shah, Hassan Alkhateeb, Aref Al-Kali

{"title":"Clinical outcomes of patients diagnosed with SETBP1 mutated myeloid neoplasms.","authors":"Yazan Jabban, Mahmoud Yacout, Anmol Baranwal, Rong He, David Viswanatha, Patricia Greipp, Dragan Jevremovic, Kurt Bessonen, James Foran, Jeanne Palmer, Antoine N Saliba, Mehrdad Hefazi-Torghabeh, Kebede Begna, William J Hogan, Abhishek Mangaonkar, Mrinal Patnaik, Mithun Shah, Hassan Alkhateeb, Aref Al-Kali","doi":"10.1080/10428194.2024.2425048","DOIUrl":"https://doi.org/10.1080/10428194.2024.2425048","url":null,"abstract":"SETBP1 mutations (m) have been previously reported in myeloid neoplasms and are associated with poor prognostic co-mutations and cytogenetic abnormalities. We retrospectively analyzed the charts of 113 patients diagnosed with myeloid neoplasms with SETBP1m. The most common diagnosis was MDS (31%). Cytogenetics were abnormal in 51 cases (46.4%), with monosomy 7 being the most common (41.1%). The most frequent co-mutations were ASXL1 (71.7%), SRSF2 (46.9%), TET2 (20.4%). Higher SETBP1m VAF was associated with proliferative features (p < 0.05). Most SETBP1m (96.5%) were in one of three hotspots (Asp868, Gly870, Ile871), with Asp868m being most frequent (51.3%). Patients with Ile871m had higher number of co-mutations (median= 4) compared to Asp868m and Gly870m (p = 0.07). On multivariate analysis, age ≥ 70 years (p = 0.004) and higher peripheral blood blasts (p = 0.02) had worse OS. Patients with Ile871m had lower OS when compared with Asp868m and Gly870m (5.5 months vs. 17.4 and 17 months, respectively, p = 0.1).","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":null,"pages":null},"PeriodicalIF":2.2,"publicationDate":"2024-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142591040","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Single-cell sequencing applications in acute myeloid leukemia. 单细胞测序在急性髓性白血病中的应用

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2024-11-04 DOI: 10.1080/10428194.2024.2422833

Nicolas Lecornec, Matthieu Duchmann, Raphael Itzykson

引用次数: 0

Safety and efficacy of acalabrutinib and obinutuzumab in treatment-naive chronic lymphocytic leukemia: a Japanese phase 1 study. 阿卡布替尼和奥比妥珠单抗对非治疗性慢性淋巴细胞白血病的安全性和有效性：日本的一项 1 期研究。

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2024-11-01 Epub Date: 2024-07-01 DOI: 10.1080/10428194.2024.2370436

Jun Takizawa, Takanori Teshima, Daisuke Ennishi, Satoshi Ichikawa, Ritsuro Suzuki, Akira Kojima, Yusuke Takahashi, Nobuya Hayashi, Hisashi Kawasumi, Kosho Murayama, Patricia Cheung, Toshio Kawata, Koji Izutsu

{"title":"Safety and efficacy of acalabrutinib and obinutuzumab in treatment-naive chronic lymphocytic leukemia: a Japanese phase 1 study.","authors":"Jun Takizawa, Takanori Teshima, Daisuke Ennishi, Satoshi Ichikawa, Ritsuro Suzuki, Akira Kojima, Yusuke Takahashi, Nobuya Hayashi, Hisashi Kawasumi, Kosho Murayama, Patricia Cheung, Toshio Kawata, Koji Izutsu","doi":"10.1080/10428194.2024.2370436","DOIUrl":"10.1080/10428194.2024.2370436","url":null,"abstract":"This report focuses on part 3 of a multicenter, open-label, phase 1 study (NCT03198650) assessing the safety, pharmacokinetics (PK), pharmacodynamics (PD), and antitumor activity of acalabrutinib plus obinutuzumab in Japanese patients with treatment-naive (TN) chronic lymphocytic leukemia (CLL). Ten patients were included; median age was 68 years. With a median treatment duration of 27.2 months, treatment-emergent adverse events (AEs) occurred in all patients (grade ≥3, 70%), and the most common AEs were anemia and headache (40% each). One patient had a grade 4 AE of neutropenia (the only dose-limiting toxicity). PK results suggested no marked effects of concomitant obinutuzumab treatment on the exposure of acalabrutinib. PD assessment indicated that combination therapy provided >98% Bruton tyrosine kinase (BTK) occupancy. Overall response rate (ORR) was 100% with median duration of response (DoR) and median progression-free survival (PFS) not reached. Treatment with acalabrutinib plus obinutuzumab was generally safe and efficacious in adult Japanese patients with TN CLL.","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":null,"pages":null},"PeriodicalIF":2.2,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141476914","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Bridging the gap: understanding contemporary autopsies in acute leukemia by comparing ante-mortem and post-mortem profiles. 缩小差距：通过比较死前和死后特征了解急性白血病的当代尸检。

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2024-11-01 Epub Date: 2024-07-01 DOI: 10.1080/10428194.2024.2372408

Deepthi Suresh, Pulkit Rastogi, Amanjit Bal, Deepesh Lad, Shano Naseem, Arihant Jain, Alka Rani Khadwal, Pankaj Malhotra

{"title":"Bridging the gap: understanding contemporary autopsies in acute leukemia by comparing ante-mortem and post-mortem profiles.","authors":"Deepthi Suresh, Pulkit Rastogi, Amanjit Bal, Deepesh Lad, Shano Naseem, Arihant Jain, Alka Rani Khadwal, Pankaj Malhotra","doi":"10.1080/10428194.2024.2372408","DOIUrl":"10.1080/10428194.2024.2372408","url":null,"abstract":"This study investigates acute myeloid leukemia/lymphoblastic leukemia (AML/ALL) through a 14-year analysis (2009-2022) of 46 autopsied cases (age >12 years). B-ALL was the dominant subtype (34.8%). Liver and spleen were the common sites of active leukemia (63% cases). Symptoms like dyspnea and altered sensorium associated significantly with heart (p = .031) and brain leukostasis (p = .006). Measurable residual disease (MRD) negativity correlated with disease-free status outside the bone marrow, while MRD-positive cases displayed leukemic infiltrates. Infections were identified in 23 autopsied cases, notably linked to post-induction and post-transplant fatalities. Surprisingly, 18 of these 23 cases had unexpected infections mainly fungal (13 cases) with Aspergillus species as the most common. Diagnostic discrepancies were identified in 48% of cases. Malignant infiltration (46%) and infections (25%) were the leading causes of death. This research sheds light on leukemia in extra-medullary tissues, uncovers novel clinical-pathological associations, and highlights overlooked therapy side effects, offering insights for future case management.","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":null,"pages":null},"PeriodicalIF":2.2,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141469202","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Development and testing of a lymphoma clinical trial-specific frailty index: a secondary analysis of the NCIC-CTG LY.12 clinical trial. 开发和测试淋巴瘤临床试验专用虚弱指数：对 NCIC-CTG LY.12 临床试验的二次分析。

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2024-11-01 Epub Date: 2024-07-09 DOI: 10.1080/10428194.2024.2370437

Abi Vijenthira, Xinzhi Li, Michael Crump, Annette E Hay, Lois Shepherd, Ralph M Meyer, Marina Djurfeldt, Bingshu E Chen, Anca Prica

{"title":"Development and testing of a lymphoma clinical trial-specific frailty index: a secondary analysis of the NCIC-CTG LY.12 clinical trial.","authors":"Abi Vijenthira, Xinzhi Li, Michael Crump, Annette E Hay, Lois Shepherd, Ralph M Meyer, Marina Djurfeldt, Bingshu E Chen, Anca Prica","doi":"10.1080/10428194.2024.2370437","DOIUrl":"10.1080/10428194.2024.2370437","url":null,"abstract":"The prevalence of frailty in clinical trials of lymphoma is unknown. We conducted a secondary analysis of the phase III LY.12 trial in which patients with relapsed aggressive non-Hodgkin lymphoma were randomized to different salvage regimens before autologous stem cell transplant. The primary objective was to construct a lymphoma clinical trials-specific frailty index (LyFI) using previously described methods. The secondary objective was to describe the association of frailty withover all and event-free survival (OS, EFS). The LyFI was constructed using 619 patients, and11% (N = 70) were classified as frail. Frailty was associated with EFS (HR 1.94, 95%CI 1.53-2.46) and OS (HR 2.01, 95%CI 1.57-2.58) in univariable analysis, but was only significant as a continuous (not binary) variable in multivariable analysis controlling for prognostic score, suggesting limitations of a FI in this trial population. Future work could validate the FI using clinical assessments and/or apply it to an older trial population.","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":null,"pages":null},"PeriodicalIF":2.2,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141563670","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Acute myeloid leukemia (AML) with chromosome 3 inversion: biology, management, and clinical outcome. 伴有 3 号染色体倒置的急性髓性白血病（AML）：生物学、管理和临床结果。

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2024-11-01 Epub Date: 2024-07-04 DOI: 10.1080/10428194.2024.2367040

Abdulrahman Alhajahjeh, Jan Philipp Bewersdorf, Rebecca P Bystrom, Amer M Zeidan, Shai Shimony, Maximilian Stahl

{"title":"Acute myeloid leukemia (AML) with chromosome 3 inversion: biology, management, and clinical outcome.","authors":"Abdulrahman Alhajahjeh, Jan Philipp Bewersdorf, Rebecca P Bystrom, Amer M Zeidan, Shai Shimony, Maximilian Stahl","doi":"10.1080/10428194.2024.2367040","DOIUrl":"10.1080/10428194.2024.2367040","url":null,"abstract":"Acute myeloid leukemia (AML) is a complex hematological malignancy characterized by diverse genetic alterations, each with distinct clinical implications. Chromosome 3 inversion (inv(3)) is a rare genetic anomaly found in approximately 1.4-1.6% of AML cases, which profoundly affects prognosis. This review explores the pathophysiology of inv(3) AML, focusing on fusion genes like GATA2::EVI1 or GATA2::MECOM. These genetic rearrangements disrupt critical cellular processes and lead to leukemia development. Current treatment modalities, including intensive chemotherapy (IC), hypomethylating agents (HMAs) combined with venetoclax, and allogeneic stem cell transplantation are discussed, highlighting outcomes achieved and their limitations. The review also addresses subgroups of inv(3) AML, describing additional mutations and their impact on treatment response. The poor prognosis associated with inv(3) AML underscores the urgent need to develop more potent therapies for this AML subtype. This comprehensive overview aims to contribute to a deeper understanding of inv(3) AML and guide future research and treatment strategies.","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":null,"pages":null},"PeriodicalIF":2.2,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141498414","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Real-world treatment patterns and outcomes for patients with CLL using the Australian pharmaceutical benefits scheme (PBS) dataset. 利用澳大利亚药品福利计划 (PBS) 数据集，为 CLL 患者提供真实世界的治疗模式和结果。

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2024-11-01 Epub Date: 2024-07-05 DOI: 10.1080/10428194.2024.2374040

Constantine Tam, Fei-Li Zhao, Safee Azam, Shu Chuen Li, Boxiong Tang

{"title":"Real-world treatment patterns and outcomes for patients with CLL using the Australian pharmaceutical benefits scheme (PBS) dataset.","authors":"Constantine Tam, Fei-Li Zhao, Safee Azam, Shu Chuen Li, Boxiong Tang","doi":"10.1080/10428194.2024.2374040","DOIUrl":"10.1080/10428194.2024.2374040","url":null,"abstract":"This real-world retrospective cohort study using Australian Pharmaceutical Benefits Scheme (PBS) 10% investigated changes in chronic lymphocytic leukemia (CLL) treatment by line of therapy, time-to-next-treatment, treatment duration, and overall survival (OS). Overall, 803 patients received their first PBS-reimbursed CLL medication between 1 January 2011 to 31 July 2021 (median age: 70 years; 64.6% male), 289 post-1 August 2020. In 2011, most first-line (1 L) prescribing was fludarabine, cyclophosphamide, and rituximab (FCR). By 2021, common 1L were chlorambucil ± CD20 (26.1%), Bruton Tyrosine Kinase inhibitor (BTKi) (26.1%), and CD20 monotherapy (23.9%). In 2011, relapsed/refractory (R/R) CLL treatment was CD20 monotherapy or FCR. By 2021, BTKi (57.7%) and venetoclax ± CD20 (26.1%) were most common. Compared to FCR, 1 L treatment duration (Hazard Ratio) was shorter for CD20 monotherapy (1.7) or chlorambucil ± CD20 (2.5). In R/R CLL, median duration was 24 (ibrutinib) and 19 months (venetoclax). Median OS was 127 months. CLLtreatment pattern shave greatly changed in Australia since the introduction of novel therapies.","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":null,"pages":null},"PeriodicalIF":2.2,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141534757","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Elicitation of societal preferences for chronic lymphocytic leukemia's treatments: a discrete choice experiment. 慢性淋巴细胞白血病治疗的社会偏好激发：离散选择实验。

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2024-11-01 Epub Date: 2024-07-09 DOI: 10.1080/10428194.2024.2374041

Ludovica Borsoi, Francesco Costa, Carlo Milano, Gaia Segantin, Paolo Ghia, Patrizio Armeni

{"title":"Elicitation of societal preferences for chronic lymphocytic leukemia's treatments: a discrete choice experiment.","authors":"Ludovica Borsoi, Francesco Costa, Carlo Milano, Gaia Segantin, Paolo Ghia, Patrizio Armeni","doi":"10.1080/10428194.2024.2374041","DOIUrl":"10.1080/10428194.2024.2374041","url":null,"abstract":"The overall value of treatments for chronic lymphocytic leukemia (CLL) depends on several factors, including preferences of the general population, who contributes to the financing of health systems. This study investigated societal preferences for attributes of CLL treatments in Italy. An online large-scale survey was designed using a discrete choice experiment (DCE) methodology and delivered to the Italian adult general population. Ten treatment attributes were identified, covering efficacy, safety, operational aspects and (hypothetical) out-of-pocket cost. DCE data were analyzed using a mixed logit regression model, estimating the willingness-to-pay for attribute levels' change. The general population significantly preferred more effective treatments, with shorter duration, administered orally rather than orally + intravenously. Changes in therapy duration, frequency of checkups and organ damage risk had the greatest impact on preferences. The integration of societal preferences in the value judgments of CLL therapies may help health authorities in establishing priority setting and taking pricing-reimbursement decisions.","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":null,"pages":null},"PeriodicalIF":2.2,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141559090","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0